LifeStance Health (LFST) Gains from Sales and Divestitures (2021 - 2024)

LifeStance Health has disclosed Gains from Sales and Divestitures across 4 years of filings, most recently posting $7.2 million for Q4 2024.

• In Q4 2024, Gains from Sales and Divestitures rose 77990.19% year-over-year to $7.2 million; the TTM figure through Dec 2024 stood at $7.2 million (up 77990.19% YoY), while the FY2024 annual figure was $7.2 million, up 77990.19% from the prior year.
• Gains from Sales and Divestitures advanced to $7.2 million in Q4 2024, from $7.1 million in the prior quarter.
• Over the last five years, Gains from Sales and Divestitures for LFST reached as high as $7.2 million in Q4 2024 and fell as low as $106.0 in Q4 2021.
• The 4-year median for Gains from Sales and Divestitures is $9179.0 (2023), against an average of $1.4 million.
• Annual changes were most pronounced in 2023 — Gains from Sales and Divestitures slumped 98.22% — and 2024, when it surged 332278.73%.
• A 4-year view of Gains from Sales and Divestitures shows it stood at $106.0 in 2021, then surged by 1979.25% to $2204.0 in 2022, then surged by 319.56% to $9247.0 in 2023, then soared by 77990.19% to $7.2 million in 2024.
• According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered $7.2 million, $7.1 million, and $13000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.